Literature DB >> 19444623

Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.

C E Holmes1, J E Levis, D L Ornstein.   

Abstract

Increased platelet counts and systemic coagulation activation are associated with ovarian cancer progression. Platelet activation occurs in the tumor microenvironment and may influence local invasion and metastasis. We used a cellular model of tumor invasion to investigate the effect of activated platelets on the human ovarian cancer cell line, SKOV3. SKOV3 cells were exposed to washed, thrombin receptor activating peptide (TRAP)-activated or TRAP-naïve platelets under various experimental conditions, and tumor cell invasion was assayed in Matrigel chambers. The effect of platelets on the content of urokinase plasminogen activator (uPA) and VEGF in SKOV3 cell conditioned medium was measured using an ELISA assay. TRAP-activated platelets stimulated a dose-dependent increase in SKOV3 cell invasion. Exposure to activated platelet membranes and to soluble proteins contained in activated platelet releasate both contributed to the observed increase in invasion. The inhibition of platelet activation with prostaglandin E1 (PGE(1)) attenuated the invasive capacity of SKOV3 cells. Exposure to platelets resulted in significantly increased uPA and VEGF content of SKOV3 cell conditioned medium. Activated platelets enhance SKOV3 human ovarian cancer cell invasion through Matrigel and increase the amount of uPA and VEGF secreted into SKOV3 cell conditioned medium. If generalizable to additional cell lines and human disease, this observation may partially explain the adverse prognosis associated with thrombocytosis in ovarian cancer. Platelets, therefore, may represent a potential target for therapeutic intervention in human ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19444623     DOI: 10.1007/s10585-009-9264-9

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  57 in total

1.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Authors:  T B Pustilnik; V Estrella; J R Wiener; M Mao; A Eder; M A Watt; R C Bast; G B Mills
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

2.  Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta.

Authors:  Sheng-Ru Shiou; Pran K Datta; Punita Dhawan; Brian K Law; Jonathan M Yingling; Dan A Dixon; R Daniel Beauchamp
Journal:  J Biol Chem       Date:  2006-09-07       Impact factor: 5.157

3.  Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.

Authors:  Mohit Trikha; Zhao Zhou; Jozsef Timar; Erzebet Raso; Margaret Kennel; Eva Emmell; Marian T Nakada
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

4.  Functional relationship between cyclic AMP-dependent protein phosphorylation and platelet inhibition.

Authors:  W Siess; E G Lapetina
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

Review 5.  Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype.

Authors:  Mary Lynn Nierodzik; Simon Karpatkin
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

6.  Platelet factors induce chemotactic migration of murine mammary adenocarcinoma cells with different metastatic capabilities.

Authors:  M A Sarach; R A Rovasio; A R Eynard
Journal:  Int J Exp Pathol       Date:  1993-10       Impact factor: 1.925

7.  Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invasion in an uPA-dependent manner.

Authors:  Orlando D Gil; Catherine Lee; Edgardo V Ariztia; Feng-Qiang Wang; Phillip J Smith; Joanie Mayer Hope; David A Fishman
Journal:  Gynecol Oncol       Date:  2008-02       Impact factor: 5.482

8.  Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.

Authors:  Chris E Holmes; Joe C Huang; Thomas R Pace; Alan B Howard; Hyman B Muss
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

9.  Correlation of platelet count with second-look laparotomy results and disease progression in patients with advanced epithelial ovarian cancer.

Authors:  Nuray Bozkurt; Kunter Yuce; Mustafa Basaran; Faruk Kose; Ali Ayhan
Journal:  Obstet Gynecol       Date:  2004-01       Impact factor: 7.661

10.  Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells.

Authors:  S J Mandriota; G Seghezzi; J D Vassalli; N Ferrara; S Wasi; R Mazzieri; P Mignatti; M S Pepper
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

View more
  23 in total

1.  Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development.

Authors:  Hui Li; Zhenwen Zhao; Gang Wei; Libo Yan; Dongmei Wang; Hong Zhang; George Earl Sandusky; John Turk; Yan Xu
Journal:  FASEB J       Date:  2010-06-08       Impact factor: 5.191

2.  Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.

Authors:  Rosalba D'Alessandro; Maria Grazia Refolo; Catia Lippolis; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-24       Impact factor: 3.333

3.  Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer.

Authors:  Jing Jia; Xiongwei Zheng; Ying Chen; Lin Wang; Lu Lin; Xingming Ye; Yan Chen; Dedong Chen; Markus Dettke
Journal:  Tumour Biol       Date:  2015-06-25

4.  Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.

Authors:  S K Allensworth; C L Langstraat; J R Martin; M A Lemens; M E McGree; A L Weaver; S C Dowdy; K C Podratz; J N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2013-06-05       Impact factor: 5.482

5.  Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.

Authors:  Viren Asher; Joanne Lee; Anni Innamaa; Anish Bali
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

6.  Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer.

Authors:  Rui Wang; Rebecca L Stone; Jason T Kaelber; Ryan H Rochat; Alpa M Nick; K Vinod Vijayan; Vahid Afshar-Kharghan; Michael F Schmid; Jing-Fei Dong; Anil K Sood; Wah Chiu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

Review 7.  Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.

Authors:  J P Cata; H Wang; V Gottumukkala; J Reuben; D I Sessler
Journal:  Br J Anaesth       Date:  2013-05       Impact factor: 9.166

8.  Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients.

Authors:  Basem Azab; Neeraj Shah; Jared Radbel; Pamela Tan; Vijaya Bhatt; Steven Vonfrolio; Ayman Habeshy; Antonio Picon; Scott Bloom
Journal:  Med Oncol       Date:  2013-01-03       Impact factor: 3.064

9.  Primary melanoma tumor inhibits metastasis through alterations in systemic hemostasis.

Authors:  Jennifer M Kirstein; M Nicole Hague; Patricia M McGowan; Alan B Tuck; Ann F Chambers
Journal:  J Mol Med (Berl)       Date:  2016-04-06       Impact factor: 4.599

10.  Stage predictivity of neutrophil/lymphocyte and platelet/lymphocyte ratios in pancreatic neuroendocrine tumors.

Authors:  Kürşat Dikmen; Mustafa Kerem
Journal:  Turk J Surg       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.